Menu

Colin Goddard, Ph.D.

Executive Chair
Colin Goddard, former CEO of BlinkBio and OSI Pharmaceuticals, led Tarceva's development and OSI’s $4B acquisition by Astellas. He chairs Mission Therapeutics, serves on Endocyte's board, and holds a PhD in cancer chemotherapy.
See full team
Colin Goddard
Background

Dr. Colin Goddard is former CEO of BlinkBio, and was formerly CEO of OSI Pharmaceuticals, raising over $1.5 billion and overseeing the development, launch and commercialization of Tarceva through to OSI’s $4 billion acquisition by Astellas. Dr. Goddard also Chairs the board of Mission Therapeutics and board member of ADC company Endocyte (a Novartis company). He obtained his PhD in cancer chemotherapy in the UK and completed post-doctoral training at the NCI in Bethesda, MD.

Our Pipeline

The Future of Cancer Treatment

OS Therapies is not just addressing Osteosarcoma. With the other uses of our HER2 target cancer immunotherapy and the addition of our OST-tADC tunable Antibody Drug Conjugate silicone linker platform, we are paving the way for the next-generation of cancer treatments.
Female chemist working on osteosarcoma treatments | OS TherapiesLab technician working on cancer treatments | OS TherapiesFemale chemist working on cancer treatments